Core Viewpoint - The company is committed to enhancing operational quality, governance, and shareholder returns, aligning with national economic and financial directives to boost market confidence and support high-quality economic development [1]. Group 1: Business Focus and Product Development - The company is focusing on its core business by converting original research results into marketable products, thereby enhancing its core competitiveness [1]. - The company has received approval for its innovative transcatheter valve-in-valve product, which addresses the needs of patients with existing bioprosthetic valves, extending their durability [2]. - Multiple products, including eye biological patches and ePTFE materials, are progressing through the registration and clinical trial phases, ensuring a robust product pipeline for future growth [3]. Group 2: Shareholder Returns - The company has established a profit distribution plan for 2024, distributing a cash dividend of 0.80 yuan per share, totaling approximately 109.92 million yuan, which represents 75.12% of the net profit attributable to shareholders [4]. - The company has actively engaged in share buybacks, with the controlling shareholder increasing their stake by 124,759 shares, amounting to approximately 13.77 million yuan [5]. Group 3: Governance and Compliance - The company is enhancing its governance structure by revising internal policies and establishing new systems to ensure compliance and protect shareholder rights [6]. - The company has implemented a multi-level supervision mechanism for key personnel to ensure accountability and compliance with regulations [7]. Group 4: Investor Communication - The company has committed to transparent communication with investors, fulfilling its information disclosure obligations and ensuring the accuracy and timeliness of its reports [8]. - In the first half of 2025, the company released 27 reports and held performance briefings to engage with investors and convey its value proposition [8].